EUVIMEDEUVIMED entdecken
Fallbericht

Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series

Dario Musone iD, Valentina Nicosia, Riccardo D'Alessandro, Marco Andrietti, Paolo Francesco Steri, Carolina Ruosi, Sofia Giuliana, Claudia Elefante, Pina Cuccurullo, Antonio Treglia

Journal of Clinical Apheresis · 2024

DOI: 10.1002/jca.22134 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Apheresis, 2024. Verfasst von Dario Musone und 9 weiteren Autor:innen. Beteiligte Einrichtung: UOC Nefrologia e Dialisi, Formia, Italy. Hauptthemen laut MEDLINE: Plasmapheresis, Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Rituximab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membranous nephropathy is the most common cause of nephrotic syndrome (NS) in non‐diabetic adults; in 80% of patients it is idiopathic (PMN). PMN has an autoimmune pathogenesis, 70%‐85% of patients have increased titer of antibodies to the podocyte membrane antigen PLA2R. The etiological, prognostic and predictive role of the Ab anti‐PLA2R is demonstrated. Standard therapy consists in anti‐CD20 monoclonal antibody rituximab (RTX) combined with steroids or immunosuppressants according to the risk of progressive loss of kidney function. The immunosuppressive therapies are potentially associated to severe adverse events that lead to protocol suspension. Given their pivotal pathogenetic role, serum clearance of anti‐PLA2R with plasmapheresis could have a beneficial impact on NS, particularly in patients not requiring or tolerating standard therapies. In this series, we present three cases of PMN anti‐PLA2R related treated with a RTX plus plasmapheresis approach and demonstrate its overall effective role on anti‐PLA2R titer and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlasmapheresisGlomerulonephritis, MembranousReceptors, Phospholipase A2RituximabHumansMaleMiddle AgedFemaleAdultAutoantibodiesImmunosuppressive Agents

Stichwörter der Autor:innen

anti‐PLA2Rmembranous nephropathynephrotic syndromeplasmapheresis

Substanzen

Receptors, Phospholipase A2RituximabPLA2R1 protein, humanAutoantibodiesImmunosuppressive Agents

Autor:innen und Institutionen

  • UOC Nefrologia e Dialisi, Formia, Italy.

ORCID-Profile: Dario Musone

Zitieren

APA

Musone, D., Nicosia, V., D'Alessandro, R., Andrietti, M., Steri, P. F., Ruosi, C., Giuliana, S., Elefante, C., Cuccurullo, P., & Treglia, A. (2024). Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22134

Vancouver

Musone D, Nicosia V, D'Alessandro R, Andrietti M, Steri PF, Ruosi C, et al. Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22134

BibTeX
@article{Musone2024,
  author = {Musone, Dario and Nicosia, Valentina and D'Alessandro, Riccardo and Andrietti, Marco and Steri, Paolo Francesco and Ruosi, Carolina and Giuliana, Sofia and Elefante, Claudia and Cuccurullo, Pina and Treglia, Antonio},
  title = {Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series},
  journal = {Journal of Clinical Apheresis},
  year = {2024},
  doi = {10.1002/jca.22134}
}
Kostenlos starten →